BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25055198)

  • 21. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-enhanced ultrasound in combination with color Doppler ultrasound can improve the diagnostic performance of focal nodular hyperplasia and hepatocellular adenoma.
    Kong WT; Wang WP; Huang BJ; Ding H; Mao F; Si Q
    Ultrasound Med Biol; 2015 Apr; 41(4):944-51. PubMed ID: 25701530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interest of contrast-enhanced sonography to identify focal nodular hyperplasia with sinusoidal dilatation.
    Alberti N; Frulio N; Bioulac-Sage P; Laumonier H; Balabaud C; Perez JT; Teixeira FR; Harbonnier N; Trillaud H
    Diagn Interv Imaging; 2014 Jan; 95(1):77-83. PubMed ID: 24139183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma.
    Suh CH; Kim KW; Park SH; Shin S; Ahn J; Pyo J; Shinagare AB; Krajewski KM; Ramaiya NH
    Eur Radiol; 2018 Jan; 28(1):214-225. PubMed ID: 28726119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
    Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
    Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review.
    Guo Y; Li W; Cai W; Zhang Y; Fang Y; Hong G
    Int J Med Sci; 2017; 14(7):668-674. PubMed ID: 28824299
    [No Abstract]   [Full Text] [Related]  

  • 31. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
    Bröker MEE; Taimr P; de Vries M; Braun LMM; de Man RA; Ijzermans JNM; Dwarkasing RS
    AJR Am J Roentgenol; 2020 Jan; 214(1):81-89. PubMed ID: 31573852
    [No Abstract]   [Full Text] [Related]  

  • 35. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.
    Bioulac-Sage P; Cubel G; Balabaud C; Zucman-Rossi J
    Semin Liver Dis; 2011 Feb; 31(1):91-103. PubMed ID: 21344354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma.
    van den Esschert JW; van Gulik TM; Phoa SS
    Dig Surg; 2010; 27(1):46-55. PubMed ID: 20357451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-phenotype correlations in hepatocellular adenoma: an update of MRI findings.
    Thomeer MG; E Bröker ME; de Lussanet Q; Biermann K; Dwarkasing RS; de Man R; Ijzermans JN; de Vries M
    Diagn Interv Radiol; 2014; 20(3):193-9. PubMed ID: 24509184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular adenoma and focal nodular hyperplasia: a series of 24 patients with clinicopathological and radiological correlation.
    Ji Y; Zhu X; Sun H; Tan Y; Ma Z; Ye Q; Sujie A; Tang Z
    Chin Med J (Engl); 2000 Sep; 113(9):852-7. PubMed ID: 11776086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is gadoxetic acid-enhanced MRI limited in tumor characterization for patients with chronic liver disease?
    Kwon S; Kim YK; Park HJ; Jeong WK; Lee WJ; Choi D
    Magn Reson Imaging; 2014 Dec; 32(10):1214-22. PubMed ID: 25192607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.
    Kim MJ; Rhee HJ; Jeong HT
    AJR Am J Roentgenol; 2012 Nov; 199(5):W575-86. PubMed ID: 23096201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.